Aurora Cannabis Has Been Granted Two Licenses By The Federal Institute For Drugs And Medical Devices Under Germany's New Medical Cannabis Act For Continued Domestic Cultivation, Which Has Been Underway For Two Years Now
Portfolio Pulse from Benzinga Newsdesk
Aurora Cannabis has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices under the new Medical Cannabis Act. These licenses allow for continued domestic cultivation and the trial of additional novel cultivars at their EU GMP facility in Leuna, Germany.
July 25, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurora Cannabis has received two new licenses under Germany's Medical Cannabis Act, allowing for expanded cultivation and R&D. This positions Aurora to grow its offerings in the rapidly expanding German market.
The new licenses allow Aurora Cannabis to expand its product offerings and conduct R&D on novel cultivars, positioning the company to capitalize on the growing German medical cannabis market. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100